A unified mechanism for PARP inhibitor-induced PARP1 chromatin retention at DNA damage sites in living cells

Cell Rep. 2024 May 28;43(5):114234. doi: 10.1016/j.celrep.2024.114234. Epub 2024 May 17.

Abstract

Poly(ADP-ribose) polymerase (PARP) inhibitors (PARPis) not only suppress PARP1 catalytic activity but also prolong its association to damaged chromatin. Here, through live-cell imaging, we quantify the alterations in PARP1 dynamics and activity elicited by seven PARPis over a wide range of concentrations to deliver a unified mechanism of PARPi-induced PARP1 chromatin retention. We find that gross PARP1 retention at DNA damage sites is jointly governed by catalytic inhibition and allosteric trapping, albeit in a strictly independent manner-catalytic inhibition causes multiple unproductive binding-dissociation cycles of PARP1, while allosteric trapping prolongs the lesion-bound state of PARP1 to greatly increase overall retention. Importantly, stronger PARP1 retention produces greater temporal shifts in downstream DNA repair events and superior cytotoxicity, highlighting PARP1 retention, a complex but precisely quantifiable characteristic of PARPis, as a valuable biomarker for PARPi efficacy. Our approach can be promptly repurposed for interrogating the properties of DNA-repair-targeting compounds beyond PARPis.

Keywords: CP: Cancer; CP: Molecular biology; FRAP; PARP inhibitors; PARP1; PARP1 inhibition; PARP1 retention; PARP1 trapping; cancer; laser micro-irradiation; live-cell imaging; mathematical modeling.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Chromatin* / metabolism
  • DNA Damage*
  • DNA Repair / drug effects
  • Humans
  • Poly (ADP-Ribose) Polymerase-1* / genetics
  • Poly (ADP-Ribose) Polymerase-1* / metabolism
  • Poly(ADP-ribose) Polymerase Inhibitors* / pharmacology

Substances

  • Poly(ADP-ribose) Polymerase Inhibitors
  • Poly (ADP-Ribose) Polymerase-1
  • Chromatin
  • PARP1 protein, human